

Identifying and developing next-generation therapies that aim to significantly improve the lives of patients

RTW Biotech Opportunities Ltd (the “Company” or LSE: RTW) is an investment fund focused on identifying transformative assets across the life sciences sector. Our approach is driven by applying deep scientific and commercial expertise with a long-term investment horizon across the full (private and public) life cycle. The portfolio is managed by RTW Investments, LP, a leading healthcare-focused investment firm dedicated to solving the most challenging unmet patient needs with a track record of supporting companies developing life-changing therapies.

KEY CURRENT STATISTICS

\$785.4M

Ordinary NAV

\$2.41

NAV per ordinary share

\$2.09

Share price

+1.7%

MTD NAV per share return

\$682.1M

Market cap

\$1.1m

Daily traded volume (3m avg)

51

Number of positions >0.5%⁶

-13.1%

Premium/Discount to NAV


HISTORICAL ANNUAL PER SHARE PERFORMANCE

YTD	NAV	Share Price	R2000 Biotech ¹	Nasdaq Biotech ²	AIC Sector ³
2026	-1.9%	-3.2%	1.7%	5.9%	-1.6%
2025	35.7%	54.8%	44.6%	32.4%	18.4%
2024	-4.6%	-0.6%	2.5%	-1.4%	1.0%
2023	23.5%	16.0%	10.6%	3.7%	5.6%
2022	-10.2%	-32.0%	-31.3%	-10.9%	-12.4%
2021	-12.8%	-5.3%	-26.9%	-0.6%	-2.3%
2020	53.9%	37.2%	52.8%	25.7%	5.1%
2019	22.4%	31.7%	23.4%	12.1%	15.8%

PERFORMANCE CHARACTERISTICS

	MTD	1Y	3Y	5Y	ITD ⁴	CAGR ⁵
NAV per ord share	1.7%	34.3%	52.7%	15.6%	131.4%	13.6%
Share Price	-1.4%	54.8%	63.9%	-11.4%	101.0%	11.2%
R2000 Biotech ¹	-0.2%	52.8%	65.5%	--21.3%	57.8%	7.2%
Nasdaq Biotech ²	3.3%	41.2%	56.8%	29.4%	89.1%	10.9%
AIC Sector ³	-1.1%	14.9%	23.9%	5.4%	27.0%	3.9%

RTW BIO PERFORMANCE IN CONTEXT



1 Russell 2000 Biotechnology Index | 2 Nasdaq Biotechnology Index | 3 AIC Biotechnology & Healthcare Sector NAV TR (\$) per share | 4 Admission to the London Stock Exchange, 30/10/2019 | 5 CAGR measured from 30/10/2019 | 6 Previous factsheets displayed only “Core” positions; going forward, it will present all positions greater than 50bps exposure.

Top 10 Positions	Description	% NAV	Public/Private	Clinical Stage ¹	Proximate Catalysts ¹
	Developing medicines for people living with rare neurologic and metabolic conditions disorders.	10.7%	Public "PTCT"	Commercial	Sepience earnings
	Restoring protein expression by harnessing the body's potential with RNA medicine.	6.1%	Public "STOK"	Pivotal	Reg update Q1 2026
	RTW-incubated biotech company committed to bringing innovative therapies to underserved patients with cardiometabolic diseases.	5.9%	Private	Phase 3	CX11 P2 data Q3 2026
	Developing antibody-based medicines to treat autoimmune diseases.	5.4%	Public "ARGX"	Commercial	Vygart Earnings
	Biotech company developing innovative solutions to treat urothelial and specialty cancers.	4.8%	Public "URGN"	Commercial	Zusduri earnings
	RTW co-incubated biopharma developing broad pipeline to treat obesity and related metabolic conditions.	3.5%	Private	Phase 3	China P3 data mid 2026
	Commercial biotech focused on serious and rare diseases.	3.4%	Public "INSM"	Commercial	BRINSUPRI earnings
	Developing therapies to address cellular abnormalities that drive tumour growth.	3.0%	Public "CELC"	Phase 3	P3 data Q2 2026
	Developing therapies for bladder cancer.	2.8%	Public "CGON"	Phase 3	P3 topline data H1 2026
	Developing novel PRAME immunotherapies for patients with cancer.	2.8%	Public "IMTX"	Phase 3	P3 data update H1 2026

% of NAV based on economic exposure

¹ Updated quarterly

Sub-portfolio Exposures ²		As of month-end	
Public		78.7%	
Private		24.3%	
Royalties		2.0%	

Sub-portfolio Attribution ²		MTD	YTD
Public		2.0%	-1.9%
Private		0.0%	0.1%
Royalties		0.0%	0.0%


Top 3 Contributors ²		YTD
Stoke Therapeutics		+0.8%
Evommune		+0.8%
CG Oncology		+0.5%

Top 3 Detractors ²		YTD
PTC Therapeutics		-1.3%
Insmed		-0.6%
Argenx		-0.6%


² Public exposure/attribution was previously broken down between "Core" and "Other" public; they are now consolidated. Contributors & detractors also reflect the full portfolio. Attribution is gross.

EXPOSURES³


Subsector Exposure (%)



Geographic Exposure (%)



Market Capitalisation Exposure (%)



Exposure by Modality

Small Molecule	54%
Antibody	21%
^Genetic Medicine	11%
Medtech	7%
Cell Therapy	3%
Proteins	1%
Other	1%
Radiotherapy	1%
Targeted Protein Degradation	1%

^ Includes gene and RNA therapies

Exposure by Disease Area

Neurology	24%
Oncology	22%
Inflammation & Immunology	21%
Metabolic	12%
Rare Disease	5%
Cardiovascular	5%
Other	4%
Pulmonary	4%
Ophthalmology	3%

Exposure by Development Stage

Preclinical	1%
Phase 1	8%
Phase 2	13%
Phase 3/Pivotal	34%
Commercial	44%

³ Exposures are calculated on positions greater than 0.5%, adjusted to sum to 100%, based on economic exposure. Except for development stage and subsector, exposures do not include royalty vehicles.

SECTOR UPDATE

Biotechnology indices outperformed broader equity markets in February and are outperforming year-to-date. The move appears to reflect a rotation away from mega-cap growth and AI-exposed tech names in favour of a more diversified group of sectors including healthcare. Furthermore, declining long term yields supported biotech companies, given their long-duration cash flow profile. Together, these dynamics have begun to re-engage generalist investors who had remained underweight in the space for the past several years.

Capital markets activity has remained constructive. Year-to-date, 46 biotech transactions totalling more than \$8 billion have been completed, including six IPOs. Approximately two thirds of IPOs year-to-date are trading above offer price, a marked improvement versus early 2025, when issuance was more muted and aftermarket performance less durable. The tentative reopening of the IPO window and improved follow-on performance reflect a gradual normalisation of risk appetite and improving institutional participation.

M&A activity also remained robust in February, with two announced transactions: Eli Lilly's acquisition of private RNA therapeutics company Orna Therapeutics for up to \$2.4 billion and Gilead's \$7.8 billion acquisition of Arcellx, a post-Phase 2 oncology company. Year-to-date, five acquisitions totalling up to \$14 billion have been announced. The Arcellx transaction reinforces continued large-cap appetite for validated clinical-stage assets. The sustained pace of deal activity underscores the need for pipeline replenishment across large biopharma with impending material patent cliffs.

PERFORMANCE UPDATE

Relative underperformance during the month was concentrated in our commercial-stage therapeutics holdings, reflecting mark-to-market pressure rather than evidence of permanent impairment. Winter prescription dynamics, including annual copay resets and periods of severe weather, weighed on prescription volumes across parts of the portfolio. However, we believe this seasonal softness was consistent with prior years and does not alter the underlying demand trajectory. We remain optimistic on our commercial portfolio, where launch trajectories and underlying fundamentals continue to progress favourably despite near-term volatility.

Within our clinical portfolio, we maintain a robust catalyst calendar for 2026, with multiple value-inflecting events ahead. We believe this positions the portfolio well to benefit from continued strategic activity and improving risk appetite across development-stage biotechnology.

Key RTW personnel for RTW Biotech Opportunities Ltd:

Roderick Wong, MD, Portfolio Manager; Naveen Yalamanchi, MD, Portfolio Manager; Peter Fong, PhD, RTW President; Stephanie Sirota, Chief Business Officer; Woody Stileman, Managing Director, Business Development; Oliver Kenyon, Senior Director, Business & Corporate Development; Krisha McCune, Director, Investor Relations

Board of Directors:

William Simpson, Chair; Chair of the Sustainability Committee; Paul Le Page, Chair of the Audit Committee; William Scott, Chair of the Nomination and Remuneration Committee; Nicola Blackwood, Senior Independent Director; Stephanie Sirota, Non-Executive Director

FUND INFORMATION

Structure: Closed-End Investment Fund	Financial Year End: 31 December	RTW Investments
Domicile: Guernsey	Interim end: 30 June	Woody Stileman +44 (0) 7717 417711
Listing: London Stock Exchange	Dividend policy: To be reinvested	Oliver Kenyon +44 (0) 2079 596362
Launch date: 30 October 2019		Krisha McCune +1 646 593 7998
SEDOL: BKTRRM2	Investment Manager: RTW Investments, LP	Deutsche Numis
ISIN: GGOOBKTRRM22	Corporate Brokers: Deutsche Numis & BofA	Priyesh Parmar (Sales) +44 (0) 2072 601648
Ticker: RTW	Distribution & IR Partner: Cadarn Capital	BofA
Index inclusion: FTSE 250, FTSE All-Share		Edward Peel +44 (0) 2076 281000
Currency: USD		Cadarn Capital
Management fee: 1.25%		David Harris (Distribution) +44 (0) 7368 883211
Performance fee: 20% with 8.0% hurdle		Lucy Clark (PR) +44 (0) 7984 184461
Ongoing Charges Ratio: 1.75% (AIC methodology)		

DISCLAIMERS

This factsheet is not intended to offer or to promote the offer or transfer of the shares (the "shares") of RTW Biotech Opportunities Ltd (the "Company") in the United States or to any "U.S. Persons" ("US persons") as defined in Regulation S under the Securities Act of 1933 (the "1933 Act").

No part of this factsheet may be reproduced in any manner without the written permission of the Company. The possession or distribution of this factsheet in certain jurisdictions may be restricted by law and persons into whose possession this factsheet comes should inform themselves about and observe any applicable restrictions. This factsheet does not constitute or form a part of any offer to sell, or any solicitation of any offer to purchase or otherwise acquire, securities in any jurisdiction. The securities described in this factsheet may not be eligible for sale in certain jurisdictions or suitable for all types of investors. The Company has not been and will not be registered under the US Investment Company Act of 1940 (the "Investment Company Act") and the Shares have not been and will not be registered under the Securities Act, or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered, sold, resold, pledged, transferred or delivered, directly or indirectly, into or within the United States or to, or for the account or benefit of, any US Persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the 1933 Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States and in a manner which would not require the Company to register under the Investment Company Act. There has been and will be no public offer of the Shares in the United States. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. This factsheet was prepared using the financial and other information available to the Company and RTW Investments, LP as at the date of this factsheet. The Shares are compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in EU Directive 2014/65/EU on markets and financial instruments, as amended (the "Target Market Assessment"). The Shares are traded on the Main Market of the London Stock Exchange. A key information document in respect of the Shares has been prepared by RTW Investments, LP and is available to investors at www.rtwbio.com. This information in this document is believed to be accurate but has not been audited by any third party. This factsheet may describe past performance, which cannot be relied on as a guide to future performance. This factsheet may include statements regarding investment strategies, individual securities and economic and market conditions; however, there can be no guarantee that such statements will prove to be correct. This factsheet may include expressions of opinions that are speculative in nature and should not be relied on as statements of fact. This factsheet may include forward-looking statements which are subject to known and unknown risks and uncertainties that may cause actual results and events to differ materially from those expressed in or implied by such forward-looking statements. In some cases, forward-looking statements can be identified by words like "will seek", "will target", "believe", "expect", "intend", or similar expressions. You should not place undue reliance on forward-looking statements. Each of the Company and RTW Investments, LP disclaim any obligation to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. Neither the Company nor RTW Investments, LP accepts any liability for actions taken on the basis of the information provided in this factsheet. The information provided in this factsheet should not be considered a recommendation to buy, sell or hold any security.